Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Immunotherapy is Scopus-indexed (Q2, CiteScore 4.2), WoS SCIE. Published by Taylor and Francis Ltd..
Checked against the index lists dated .
ISSN 1750-743XVerify ISSN ↗1750-7448Verify ISSN ↗
Publisher: Taylor and Francis Ltd.
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 206 / 428 | 51st | Q2 |
| Immunology and Allergy | 132 / 234 | 43rd | Q3 |
| Immunology | 148 / 243 | 39th | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2009–present, best quartile Q2, CiteScore 4.2.
Immunotherapy is Q2 in Oncology (rank 206 of 428), Q3 in Immunology and Allergy (rank 132 of 234) and Q3 in Immunology (rank 148 of 243), by CiteScore 2025.
Immunotherapy is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.2, which places it in quartile Q2 at the 51st percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.666, quartile Q3, with an H-index of 75.
Immunotherapy is published by Taylor and Francis Ltd. Its print ISSN is 1750-743X and its online ISSN is 1750-7448.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Immunotherapy has an h-index of 82 and a 2-year mean of 2.45 citations per paper (OpenAlex). Its Scopus CiteScore is 4.2, quartile Q2. On 2-year citations it ranks #154 of 424 Scopus journals in Oncology.
Immunotherapy published 135 papers in 2025; its busiest recent year was 2020 with 162. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2025–2026), authors are most often from China (21.2%), United States (18.5%) and Türkiye (9.6%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.